Evaluating a Shorter, Rifampicin-Based Treatment for People With Less Severe Tuberculosis Disease
Status:
NOT_YET_RECRUITING
Trial end date:
2030-01-31
Target enrollment:
Participant gender:
Summary
RIFAstrat is a Phase 3, double-blind, placebo-controlled, non-inferiority trial to compare the 6-month standard treatment for DS-TB with a 4-month optimised- rifampicin based regimen provided to individuals with limited disease severity.
Phase:
PHASE3
Details
Lead Sponsor:
Hamilton Health Sciences Corporation
Collaborators:
McMaster University St George's, University of London